New Specialty Pharmacy Medical Step Therapy Requirements (Healthy Blue + Medicare HMO D-SNP)
Please note, this communication applies to Healthy Blue + Medicare℠ (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina.
Effective April 1, 2023, the following Medicare Part B medications from the current Clinical Criteria guidelines will be included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for consumers who are actively receiving medications listed below.
Clinical Criteria CC-0072 currently has a step therapy preferring Avastin and Eylea. This update is to notify that Byooviz, Cimerli, Lucentis, and Vabysmo will be added to existing step therapy as preferred agents.
Clinical Criteria guidelines are publicly available. Visit Anthem's Clinical Criteria to search for specific criteria. For more information, please see Anthem's Medical Drug Clinical Criteria (PDF).
| Clinical Criteria Guidelines | Preferred drug(s) | Nonpreferred drugs(s) |
|---|---|---|
| CC-0072 (PDF) | Avastin | Beovu |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.